# Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

> **NCT02671890** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 16 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma
- Refractory Malignant Solid Neoplasm
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **DRUG:** Chemotherapy
- **DRUG:** Disulfiram
- **DRUG:** Gemcitabine Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02671890
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-25
- **Primary completion:** 2024-05-08
- **Final completion:** 2024-11-11
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** lack of funding
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02671890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02671890, "Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02671890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*